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he transcription factor 
 
Microphthalmia
 
-associated
transcription factor (MITF) is a lineage-determination
factor, which modulates melanocyte differentiation
and pigmentation. MITF was recently shown to reside down-
stream of the canonical Wnt pathway during melanocyte
differentiation from pluripotent neural crest cells in zebraﬁsh
as well as in mammalian melanocyte lineage cells. Although
expression of many melanocytic/pigmentation markers is
lost in human melanoma, MITF expression remains intact,
even in unpigmented tumors, suggesting a role for MITF
beyond its role in differentiation. A signiﬁcant fraction of
 
primary human melanomas exhibit deregulation (via aberrant
T
 
nuclear accumulation) of 
 
 
 
-catenin, leading us to examine
its role in melanoma growth and survival. Here, we show
that 
 
 
 
-catenin is a potent mediator of growth for melanoma
cells in a manner dependent on its downstream target
MITF. Moreover, suppression of melanoma clonogenic
 
growth by disruption of 
 
 
 
-catenin–T-cell transcription factor/
LEF is rescued by constitutive MITF. This rescue occurs
largely through a prosurvival mechanism. Thus, 
 
 
 
-catenin
regulation of MITF expression represents a tissue-restricted
pathway that signiﬁcantly inﬂuences the growth and survival
behavior of this notoriously treatment-resistant neoplasm.
 
Introduction
 
Among cancers, melanoma is well known both for its rapidly
increasing incidence and its resistance to virtually all but
surgical therapies. Melanoma arises from melanocytes, neu-
ral crest derived pigment cells in the skin and eye. During
melanoma carcinogenesis, many of the normal markers of
the melanocyte lineage are lost, but most if not all melanomas
retain expression of the basic/helix-loop-helix/leucine-zipper
(bHLHzip)* transcription factor 
 
Microphthalmia
 
-associated
transcription factor (MITF) (King et al., 1999). MITF was
first identified in mouse as a locus whose mutation results
in absence of pigment cells causing white coat color and
deafness due to melanocyte deficiency in the inner ear
(Hodgkinson et al., 1993). In humans, mutation of MITF
results in Waardenburg Syndrome IIa, a condition charac-
terized by white forelock and deafness (Hughes et al., 1994).
Recent studies have elucidated a network of genes thought
to regulate expression or activity of MITF (for review see
Goding, 2000). Mutation of many of these genes, including
Pax3, Sox10, endothelin-3, c-Kit, or endothelin receptor B,
produces very similar pigmentation deafness syndromes in
humans due to loss of viable melanocytes (for review see
Price and Fisher, 2001).
A role for MITF in pigment gene regulation has been
strongly suggested (Bentley et al., 1994; Hemesath et al.,
1994; Yasumoto et al., 1994, 1997) based on the existence of
highly conserved MITF consensus DNA binding elements in
the promoters of the three major pigment enzyme genes: ty-
rosinase, Tyrp1, and Dct. Mounting evidence also suggests a
role for MITF in the commitment, proliferation, and sur-
vival of melanocytes before and/or during neural crest cell
migration (Opdecamp et al., 1997). Moreover, examina-
tion of heterozygous mutant MITF mice shows that abso-
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lute numbers of melanoblasts are reduced (Hornyak et al.,
2001), suggesting a dosage dependence on MITF. Collec-
tively, these studies suggest that MITF, in addition to its
role in differentiation pathways such as pigmentation, may
serve an important role in the proliferation and/or survival
of developing melanocytes. The retention of MITF expres-
sion in the vast majority of human primary melanomas, in-
cluding nonpigmented tumors, is consistent with this possi-
bility and has also led to the widespread use of MITF as a
diagnostic tool in this malignancy (King et al., 1999; Salti et
al., 2000; Chang and Folpe, 2001; Miettinen et al., 2001).
The Wnt signaling pathway plays an integral role
throughout development (for review see Wodarz and Nusse,
1998), particularly in the neural crest (for review see Dorsky
et al., 2000a), and has also been strongly implicated in hu-
man tumorigenesis (for reviews see Bienz and Clevers, 2000;
Peifer and Polakis, 2000). Wnt signaling plays a pivotal role
in neural crest population expansion (Ikeya et al., 1997) and
melanocyte lineage-specific expansion and differentiation
(Dorsky et al., 1998; Dunn et al., 2000; Jin et al., 2001). A
key downstream effector of this pathway is 
 
 
 
-catenin, a mul-
tifunctional protein which can either bind to E-cadherins as
an integral part of the actin cytoskeleton which anchors cell–
cell adhesion, or can act as a transcriptional coactivator by
interacting with the T-cell transcription factor (TCF)/lym-
phoid enhancer binding factor (LEF) family of DNA bind-
ing proteins in the nucleus. In the absence of Wnt-signals,
 
 
 
-catenin is targeted for degradation via phosphorylation by
a complex consisting of glycogen synthase kinase (GSK)3
 
 
 
,
axin, and adenomatous polyposis coli protein (APC). Wnt
signals lead to inactivation of GSK3
 
 
 
,
 
 
 
and thus stabilize
 
 
 
-catenin levels in the cell which increase transcription of
downstream target genes. Mutations in multiple compo-
nents of the Wnt pathway have been identified in many hu-
man cancers, and share the property of inducing nuclear ac-
cumulation of 
 
 
 
-catenin (Polakis, 2000). Dysregulation of
 
 
 
-catenin levels has been shown to produce aberrant trans-
activation of downstream proto-oncogenes such as cyclin
D1 (Shtutman et al., 1999; Tetsu and McCormick, 1999)
and c-Myc (He et al., 1998). In human melanoma, stabiliz-
ing mutations of 
 
 
 
-catenin have been found in a significant
fraction of established cell lines (Rubinfeld et al., 1997). Im-
portantly, in primary human melanoma specimens, almost
one third display aberrant nuclear accumulation of 
 
 
 
-cate-
nin, although generally without evidence of direct mutations
within the 
 
 
 
-catenin gene itself (Rimm et al., 1999). These
observations are consistent with the hypothesis that this
pathway contributes to behavior of melanoma cells and
might be inappropriately deregulated in the genesis of this
disease.
During zebrafish development, Wnt signaling has been
demonstrated to be both necessary and sufficient to promote
pigment cell fate of neural crest cells through its effector
 
 
 
-catenin at the expense of neural and glial lineages (Dorsky
et al., 1998). The zebrafish MITF homologue, 
 
nacre
 
, was
shown to mediate this fate decision as a downstream target
of Wnt signaling (Dorsky et al., 2000b). In mammalian
cells, Wnt-3a, was also shown to induce MITF expression
(Takeda et al., 2000). These reports indicate that the MITF
promoter is transactivated by 
 
 
 
-catenin in a manner depen-
dent on TCF/LEF DNA consensus elements. Based on their
pivotal requirements during melanocyte development, it is
of interest to speculate that MITF and Wnt/
 
 
 
-catenin may
also play central roles in the behavior of melanoma cells.
Here we show that 
 
 
 
-catenin is a significant regulator of
melanoma cell growth, with MITF as a critical downstream
target. Importantly, disruption of the canonical Wnt path-
way abrogates growth of melanoma cells, and constitutive
overexpression of MITF rescues the growth suppression.
These observations establish a critical role for both 
 
 
 
-catenin
and MITF in cell growth and survival of human melanoma.
 
Results
 
Proliferation of melanoma cells can be altered 
by overexpression of 
 
 
 
-catenin/dnTCF
 
To assess the functional relevance of Wnt/
 
 
 
-catenin signals
governing the proliferation and survival of melanoma cells,
we began by ectopically expressing 
 
 
 
-catenin in mouse B16
melanoma cells. Additionally, we expressed a dominant-neg-
ative (dn) allele of TCF-1 (dnTCF) that is incapable of
interacting with 
 
 
 
-catenin, but retains TCF/LEF DNA
binding specificity (van de Weterling et al., 1996). B16
melanoma cells were cotransfected with a vector that directs
the expression of humanized Renilla (hr) GFP in order to
monitor the transfected cells during flow cytometry by gat-
ing on GFP-positive cells. Overexpression of 
 
 
 
-catenin re-
sulted in an increase of the S-phase fraction as compared
with vector control (26–34.5%; Fig. 1 A), whereas ectopic
expression of dnTCF resulted in a significant decrease in
S-phase content (26–17%). In parallel experiments, we per-
formed colony-forming assays, substituting hrGFP with a
puromycin resistance vector, and selected the cells for clono-
genic growth (Fig. 1 B). Ectopic expression of 
 
 
 
-catenin sig-
nificantly stimulated colony formation relative to vector
control. Conversely, addition of dnTCF was deleterious to
colony formation. Thus, 
 
 
 
-catenin stimulates proliferation
and clonogenic growth in melanoma cells, and blockade of
this pathway by dnTCF appears to be growth suppressive.
Figure 1. Overexpression of  -catenin is proliferative and pro-
survival in melanoma cells and dnTCF is inhibitory. (A) Cell cycle 
profiles of mouse B16 melanoma cells 48 h after transient transfection 
by indicated vectors and GFP as analyzed by propidium iodide 
staining and flow cytometry. (B) Representative colony-forming 
assays in mouse B16 melanoma cells. 
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We analyzed endogenous 
 
 
 
-catenin localization in the
melanomas used in this and subsequent experiments. Using
immunofluorescence we found that mouse B16 melanoma
and human A375 melanoma cells exhibit mostly cytoplas-
mic 
 
 
 
-catenin staining, whereas human 501mel and SK-
MEL-5 melanomas exhibit aberrant nuclear accumulation
in addition to cytosolic staining (Fig. 2 A). This finding is
comparable to the previous observations that demonstrated
 
 
 
-catenin within the nucleus of 
 
 
 
1/3 of primary melanoma
specimens (Rimm et al., 1999). Reporter assays were per-
formed and showed that cells without aberrant nuclear ac-
cumulation of 
 
 
 
-catenin retain a modest (approximately
twofold) but measurable degree of endogenous TCF/LEF
 
transcriptional activity (Fig. 2 B). The aberrant nuclear ac-
cumulation of 
 
 
 
-catenin in 501mel and SK-MEL-5 is asso-
ciated with significantly higher activity for the reporter con-
taining optimal TCF/LEF binding sites (TK-TOP) relative
to the one with mutated TCF/LEF sites (TK-FOP). These
experiments suggest that the 
 
 
 
-catenin–TCF/LEF transcrip-
tional pathway is activated to varying degrees among mela-
noma cell lines, a finding which is consistent with data from
primary human melanomas (Rimm et al., 1999). Moreover,
the 
 
 
 
-catenin–TCF/LEF pathway appears to be active, al-
though to a lesser extent, even in those melanomas without
excessive quantities of 
 
 
 
-catenin in the nucleus. Ectopic ex-
pression of 
 
 
 
-catenin in these human melanoma lines re-
vealed a correlation between absence of aberrant nuclear
 
 
 
-catenin and a mitogenic effect from exogenous 
 
 
 
-catenin
(Table I). The lack of a mitogenic effect for exogenous
 
 
 
-catenin in cells with aberrant nuclear accumulated 
 
 
 
-cate-
nin is consistent with the possibility that these cells are al-
ready maximally stimulated through this pathway, and there-
fore less responsive to additional (exogenous) 
 
 
 
-catenin.
However, expression of dnTCF does profoundly disrupt pro-
liferation in all tested melanoma lines (see below), suggesting
that the pathway remains important in cells exhibiting either
nuclear plus cytoplasmic or mostly cytoplasmic 
 
 
 
-catenin.
 
The MITF promoter is bound and regulated in a lineage 
specific manner by 
 
 
 
-catenin
 
The MITF promoter has recently been shown to be a down-
stream target of Wnt signaling in melanocytes (Dorsky et al.,
2000b; Takeda et al., 2000). To extend these observations,
we analyzed 
 
 
 
-catenin responsiveness of the MITF pro-
moter in B16 melanoma cells (Fig. 3 A). The MITF pro-
moter is potently activated by 
 
 
 
-catenin in a manner depen-
dent upon the TCF/LEF binding site based on deletion
mutagenesis, consistent with point mutagenesis studies of
Takeda et al. (2000). A comparison between the 
 
 
 
-catenin
responsiveness of B16 melanoma cells and epithelial BHK
cells using luciferase reporters revealed that the MITF pro-
moter is regulated in a melanocyte restricted fashion (Fig. 3
B), extending previous observations in zebrafish to mela-
noma cells (Dorsky et al., 2000b). Also in agreement with
previous reports (Dorsky et al., 2000b; Takeda et al., 2000),
the TCF/LEF site was capable of binding TCF/LEF–
 
 
 
-cate-
nin proteins in vitro as shown by DNA binding studies us-
ing nuclear extracts from B16 (mouse) or 501mel (human)
melanoma cells, as well as Jurkat (T cells) as a control (Fig. 3
B). We utilized a consensus MITF promoter fragment probe
for electrophoretic mobility shift assays. As shown in Fig. 3
C, formation of complexes could be visualized on both the
Figure 2. Localization of endogenous  -catenin in melanoma cells 
and corresponding TCF/LEF transcriptional activity. (A) Melanoma 
cells (mouse B16 melanoma, human A375, human 501mel, and 
human SK-MEL-5) were assayed by immunofluorescence for the 
localization of  -catenin. As shown, B16 and A375 do not display 
aberrant nuclear accumulation of  -catenin in comparison with 
501mel and SK-MEL-5, which display both cytoplasmic and nuclear 
 -catenin. (B) Bar graphs of the relative activity of TK-TOP, with 
optimal TCF/LEF binding sites and TK-FOP which carries mutated 
sites for TCF/LEF as an enhancer for the TK immediate early promoter 
driving luciferase.
 
Table I. 
 
Correlation between nuclear 
 
 
 
-catenin and induced proliferation in melanoma
Cell line Species Endogenous nuclear 
 
 
 
-catenin staining Proliferation induced by constitutive 
 
 
 
-catenin
 
B16 Mouse No Yes, S 
 
 
 
 
 
 
 
23% (
 
 
 
7%)
A375 Human No Yes,  S 
 
 
 
 
 
 
 
25% (
 
 
 
8%)
501mel
 
a
 
Human Yes No
SK-MEL-5 Human Yes No
 
a
 
Harbors stabilizing 
 
 
 
-catenin mutation (Rubinfeld et al., 1997).
Average proliferation is measured as induced S-phase accumulation relative to vector control transfected cells.  
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MITF promoter and TCR
 
 
 
 control probes previously iden-
tified as TCF/LEF and TCF/LEF with 
 
 
 
-catenin (Korinek
et al., 1997). In addition, inclusion of a polyclonal antibody
directed at 
 
 
 
-catenin produces a supershifted complex, high-
lighting the identity of this complex. The shifted complex
was competed with a wild-type MITF probe but not with a
probe in which the TCF/LEF site is mutated. Importantly,
nuclear extracts from melanomas with or without aberrant
nuclear 
 
 
 
-catenin both produce supershiftable 
 
 
 
-catenin
complexes, further supporting the conclusion that the Wnt/
 
 
 
-catenin/LEF pathway is functional even in melanomas ex-
hibiting predominantly cytoplasmic 
 
 
 
-catenin. To assess
whether 
 
 
 
-catenin is endogenously bound to the MITF pro-
moter in melanoma cells, we conducted chromatin immu-
noprecipitation assays in B16 melanoma cells. As shown in
Fig. 4 A, these studies revealed occupancy of the endogenous
melanocyte-specific MITF promoter by 
 
 
 
-catenin with ab-
sence of signal from control antibody, no-antibody control,
or anti–
 
 
 
-catenin tested on a remote transcriptionally active
genomic location (the tyrosinase promoter). This observa-
tion on the endogenous MITF gene is in agreement with the
previously reported ability of the architectural TCF/LEF
proteins to bind the MITF promoter in gel shift assays
(Takeda et al., 2000) and extends this further to show that
endogenous 
 
 
 
-catenin is truly found at the MITF-promoter
in melanoma cells.
 
Endogenous MITF levels are altered by constitutive 
expression of  -catenin and dnTCF
To determine whether endogenous levels of MITF expres-
sion were positively and negatively affected via  -catenin or
dnTCF in melanoma cells, we cotransfected  -catenin or
dnTCF vectors together with GFP into B16 melanoma cells,
and analyzed endogenous MITF protein expression levels by
FACS using a monoclonal antibody against MITF. Ectopic
expression of  -catenin led to a significant and reproducible
increase in MITF protein levels compared with vector con-
trol (Fig. 4 B). In contrast, expression of dnTCF led to a
measurable reduction of MITF protein levels. Taken to-
gether with recent work (Dorsky et al., 2000b; Takeda et al.,
2000), these data demonstrate that MITF expression is tar-
geted by the Wnt pathway in a manner that measurably al-
ters endogenous MITF protein levels, and therefore might-
contribute to the phenotypic effects of  -catenin–TCF/LEF
on melanoma cell growth or survival.
A novel MITF(dn) abrogates 
 -catenin–induced proliferation
During melanocyte development, MITF appears to be a
functionally critical target of Wnt signaling, as demonstrated
using rescue assays in zebrafish (Dorsky et al., 2000b). Al-
though  -catenin signaling is heavily implicated in human
malignancies, few identified downstream targets of this
pathway have been found that are lineage specific and func-
tionally important in the neoplastic state. In order to con-
duct loss-of-function experiments, we made use of a novel
dn mutation of MITF (MITF[dn]) based on a mutant
mouse allele, which deletes a critical basic domain arginine
while retaining an intact HLH-Zip dimerization motif. This
mutation is dn through sequestration of a wild-type partner
into a heterodimer that is incapable of binding DNA due to
the arginine deletion (Hemesath et al., 1994). Without af-
fecting its specificity, a further NH2-terminal truncation was
made which removes the transactivation domain. Immuno-
fluorescence revealed that the dominant negative protein lo-
Figure 3.  -catenin transactivates and binds the MITF promoter 
in vitro. (A) The TCF/LEF binding site is critical for  -catenin induced 
transactivation of the MITF promoter in B16 cells. (B)  -Catenin 
transactivation of the MITF promoter is tissue restricted, as in epithelial 
BHK cells the promoter is unresponsive to  -catenin. (C) Electro-
phoretic mobility shift assay showing that a complex formed from 
mouse B16, human 501mel, or Jurkat cell extracts on the MITF TCF/
LEF probe can be specifically supershifted using an antibody against 
 -catenin. As a control, the same extracts were used to supershift a 
probe of the previously characterized TCR  TCF/LEF binding site. 
The complex visualized by EMSA is competed away by adding a 
wild-type MITF probe but not a mutant probe.
Figure 4.  -catenin is associated with the endogenous MITF 
promoter and modulates MITF expression levels. (A) In vivo 
association of  -catenin with the mouse MITF promoter by chromatin 
immunoprecipitation. The mouse tyrosinase promoter is a transcrip-
tionally active negative control. (B) Ectopic expression of  -catenin 
leads to endogenous upregulation of MITF protein levels, and 
conversely, dnTCF downregulates MITF protein as quantitated by 
flow cytometry and analysis of transfected (gated GFP-positive) cells.MITF is a critical melanoma survival factor | Widlund et al. 1083
calizes to the nucleus in transfected melanoma cells (Fig. 5
A). In vitro transcriptional assays using an E-box–dependent
reporter demonstrated that the dn construct potently re-
presses basal activity, whereas wild-type MITF stimulates
the reporter in B16 melanoma cells (Fig. 5 B). Importantly,
the MITF(dn) construct is unable to repress the same E-box
reporter in non-MITF–expressing HEK293 cells, consistent
with its repressive effect being due to sequestration of en-
dogenous MITF away from DNA.
Because the Wnt pathway is likely important for both
proliferation and survival, we wanted to explore the conse-
quences of interfering with its downstream target MITF
by inclusion of the dn mutant, MITF(dn). To examine
whether MITF plays an important role in  -catenin’s mi-
togenic effects in melanoma cells, we transfected B16
melanoma cells with  -catenin in the presence of either
MITF(dn) or vector control. As before, cell cycle analysis re-
vealed that  -catenin overexpression leads to an increase in
S-phase relative to vector control (21–28%), but that coex-
pression of MITF(dn) abrogates this effect (down to 17%;
Fig. 5 C). Moreover, colony formation was also examined to
measure broader growth/survival effects and also demon-
strated both stimulation by  -catenin and potent repression
by MITF(dn) (Fig. 5 D), suggesting a critical dependence of
MITF for this pathway in melanoma cells.
MITF specifically rescues apoptosis induced by dnTCF
If MITF were a functionally important mediator of  -cate-
nin signaling in melanoma, then transfection of MITF-
encoding plasmid may be able to rescue the phenotype gen-
erated by blockade of the Wnt pathway. We recapitulated
 -catenin blockade using dnTCF in multiple melanoma lines
and examined the effects of simultaneous MITF expression
from a constitutive promoter. Constitutive MITF expression
significantly rescued colony formation in human 501mel
and SK-MEL-5 melanoma cells (Fig. 6 A), both of which ex-
hibit nuclear accumulated  -catenin (Table I). The same ex-
periment was also carried out in B16 melanoma cells, dis-
playing mostly cytoplasmic  -catenin. In this setting as well,
growth suppression imposed by dnTCF was similarly res-
Figure 5. MITF(dn) blocks  -catenin–induced cell proliferation 
and growth in B16 melanoma cells. (A) Ectopic expression of an 
HA-tagged MITF(dn) in B16 melanoma cells is nuclear as visualized 
by FITC–anti-HA staining (compared with nuclear staining with 
DAPI in the same high power field). (B) MITF(dn) represses the 
activity of a 4   E-box reporter that is transactivated by MITF(wt) in 
melanoma cells and this repression does not occur in the non-MITF 
expressing HEK293 cell line. (C and D) Expression of MITF(dn) 
abrogates  -catenin induced proliferation and growth in cell cycle 
analysis and clonogenic assay.
Figure 6. MITF can rescue growth 
suppression of dnTCF in melanoma 
cells. (A) Colony-forming assays in two 
human melanoma cell lines (501mel 
and SK-MEL-5) show rescue of clono-
genic survival in the presence of dnTCF 
by wild-type MITF, whereas c-Myc is 
further growth inhibitory (B) Clonogenic 
survival in B16 melanoma demonstrates 
suppression by dnTCF and rescue by wild-
type MITF, but not c-Myc (quantitative 
results are normalized to vector control). 
Experiment done in triplicate and 
quantitated results are graphed. Indi-
cated with * is significant with P   0.03 
and ** significant with P   0.01 as statis-
tically calculated using Student’s t test 
for unpaired samples. (C) Control colony 
formation assays in B16 cells showing 
growth suppressive effects of dnTCF and 
c-Myc in relation to MITF and vector 
control. (D) MITF rescues apoptosis induced by dnTCF but cannot relieve cell cycle inhibition in B16 melanoma cells. In contrast c-Myc 
bypasses dnTCF antiproliferative effects (S-phase repression), but significantly increases the apoptotic population. Apoptosis is measured as 
sub-G1 peak from propidium iodide staining. The quantitation was performed using ModFit v2.0 and represents values normalized to vector 
control as baseline. Averages from four independent experiments are presented (including error bars for standard deviation of mean). (E) Soft 
agar assay showing a representative example of macroscopic colonies of SK-MEL-5 cells 20 d after infection with the indicated retroviruses.1084 The Journal of Cell Biology | Volume 158, Number 6, 2002
cued by constitutive MITF expression, as displayed in a
quantitative summary of clonogenic growth assays (Fig. 6 B).
In contrast, c-Myc, a different downstream target of the Wnt
pathway (He et al., 1998), did not rescue growth suppression
by dnTCF in melanoma cells, and in some cases even further
suppressed clonogenic growth (Fig. 6, A and B). Control ex-
periments in B16 melanoma revealed measurable growth
suppression by both dnTCF and c-Myc (Fig. 6 C).
Cell cycle analysis was performed on the transfected
populations to further delineate the consequences of ma-
nipulating  -catenin–TCF/LEF with MITF or c-Myc. As
shown in Fig. 6 D, expression of dnTCF produces not only
a relative G1 arrest, but also a dramatic increase in apop-
totic death. Co-expression of MITF, however, produces a
significant rescue of this apoptosis while slightly increasing
the S phase cell-cycle profile. These data suggest a role for
MITF in survival and are consistent with the possibility
that other targets of the Wnt-pathway contribute to the
proliferative response in melanoma cells. Coexpression of
Cyclin D1, another downstream target of  -catenin (Shtut-
man et al., 1999; Tetsu and McCormick, 1999), did not
rescue dnTCF’s cell cycle effects (unpublished data). In
contrast, coexpression of c-Myc with dnTCF more signifi-
cantly rescues the S phase decrease observed with dnTCF,
but leads to an even greater apoptotic response than dnTCF
alone (Fig. 6 D). Despite c-Myc’s apparent mitogenic ef-
fect, its growth suppression (Fig. 6, A and B) is likely
achieved through an augmented apoptotic response. Thus,
the rescue of growth observed by expression of MITF with
dnTCF appears to be predominantly accounted for by re-
ducing apoptosis, although MITF may contribute to
 -catenin’s proliferative effects as well, because MITF(dn)
abrogates  -catenin–induced cell cycle stimulation (Fig. 5,
C and D). Soft agar growth assays were also performed to
test whether MITF’s ability to rescue dnTCF occurred for
multiple functional readouts. As shown in Fig. 6 E, MITF
also rescued dnTCF for soft agar growth. Collectively, mea-
surements of colony growth (on plastic), apoptosis, and soft
agar growth, all suggest that regulation of melanoma
growth by the  -catenin–TCF/LEF pathway is functionally
dependent on the MITF transcription factor.
Discussion
This report presents data indicating that the effector of the
Wnt signaling pathway,  -catenin, is able to stimulate
growth of melanoma cells. Coupled to the finding that
nearly one third of human primary melanoma specimens as
well as melanoma cell lines exhibit nuclear accumulation of
 -catenin (Rubinfeld et al., 1997; Rimm et al., 1999), these
data imply a significant functional role for this pathway in
human melanoma. Utilizing ectopic expression of dnTCF
we revealed an upstream-downstream relationship between
 -catenin–TCF/LEF and MITF. Abrogation of TCF/LEF-
dependent transcription suppresses growth and triggers ap-
optosis accompanied by inhibition of MITF expression.
MITF is likely a critical survival factor in the Wnt pathway,
as the apoptosis triggered by abrogating the Wnt pathway
can be rescued by reintroduction of MITF. Additionally, in-
troduction of a dominant-negative allele of MITF blocks
proliferation induced by  -catenin. These data, coupled to
the developmental rescue studies in zebrafish (Dorsky et al.,
2000b), place MITF as an essential lineage specific target of
Wnt signaling both in melanocyte development, and post-
developmentally, in melanoma.
MITF as a survival factor in the melanocyte lineage
It is noteworthy that MITF expression is retained in the vast
majority of human melanomas, including the many tumors
in which other differentiation markers, such as pigmenta-
tion, are lost (King et al., 1999). Furthermore, MITF defi-
ciency in mouse or man results in melanocyte loss (rather
than depigmentation), and one mutant mouse allele (Mitf
vit)
displays most melanocyte loss postnatally (Lerner et al.,
1986). These observations suggest that MITF may be func-
tionally important for melanoma growth or survival, a
premise that is tested here.
In addition to its Wnt responsiveness, the MITF pro-
moter responds to melanocyte stimulating hormone via a
CRE element (Bertolotto et al., 1998; Price et al., 1998).
The observation that melanoma cells are sensitized towards
apoptosis by introduction of a dn CREB (Jean et al., 1998)
is consistent with the possibility that the response may be at
least partially mediated by disruption of MITF expression.
Although the Wnt/ -catenin and CREB signaling pathways
are both ubiquitous among cell types, it is striking that their
effects on MITF expression are restricted to the melanocyte
lineage, providing an example of ubiquitous pathways which
are harnessed to regulate a tissue-restricted promoter both
during normal development and in malignancy. Recent data
have also shown direct transcriptional regulation of the pro-
survival gene BCL2 by MITF (McGill et al., 2002). Further-
more, the Wnt pathway has been shown to protect against
induction of apoptosis in an in vitro fibroblast system de-
pendent on  -catenin/TCF-mediated transcriptional activ-
ity (Chen et al., 2001). In vivo inactivation of  -catenin has
also been shown to increase apoptosis in migrating neural
crest cells (Brault et al., 2001), suggesting that in nonme-
lanocytic neural crest derivatives, Wnt/ -catenin likely em-
ploys different (non-MITF) targets to mediate anti-apop-
totic signaling.
MITF as a downstream effector of developmental 
and oncogenic pathways
As  -catenin has been shown in other systems to augment
growth, it is not surprising to find that this also pertains to
melanoma cells, where  -catenin overexpression or disrup-
tion are shown to significantly modulate both cell cycle and
survival (Figs. 1, 5, and 6). In melanomas with aberrant nu-
clear accumulation of  -catenin, further ectopic  -catenin
expression does not lead to augmented proliferation (Table
I). This could be due to the maximized basal activity of
 -catenin in these cells, as proliferation and growth is still
abrogated by introduction of dnTCF irrespective of  -cate-
nin status. Of note, there is also a correlation between the
endogenous MITF level and presence of aberrant nuclear
 -catenin in the human melanomas employed here, where
A375 (with mostly cytoplasmic  -catenin) has significantly
less MITF than the human melanoma cell lines which lack
strong nuclear  -catenin staining (unpublished data). Still,MITF is a critical melanoma survival factor | Widlund et al. 1085
MITFs transcriptional ability may be modulated by post-
translational events so that quantitative measures of MITF
may not necessarily correlate perfectly with its transcrip-
tional activity. We have also shown that  -catenin leads to
increased growth that is potently abrogated by MITF(dn),
both measured as decreased proliferation via cell cycle pro-
files and clonogenic growth. The blockade of  -catenin–
induced growth of melanoma cells by MITF(dn) suggests an
implicit need for MITF to sustain the growth of these cells.
MITF(dn) has been found to suppress melanoma growth re-
gardless of whether  -catenin’s basal activity is low or high.
Interestingly, reintroduction of MITF(wt) minimally re-
verses the alterations in cell cycle caused by suppressing the
Wnt pathway by ectopic dnTCF. This observation argues
that whereas MITF may be necessary for cell cycle progres-
sion induced by  -catenin, MITF is not sufficient to stimu-
late cell cycle progression. Therefore, it will be of interest to
determine whether there are MITF target genes, which in-
fluence cell cycle progression to examine the possibility that
MITF contributes to maintenance of the cell cycle machin-
ery while perhaps not directly participating in the mitogenic
response. Cell cycle targets of Wnt signaling such as c-Myc,
Cyclin D1 (He et al., 1998; Tetsu and McCormick, 1999;
Shtutman et al., 1999), and others may more directly medi-
ate  -catenin’s mitogenic effects. Such a model would pre-
dict that MITF, as a highly tissue-restricted factor, or its
downstream target genes, may represent attractive drug tar-
gets in melanoma, a disease for which effective therapies are
severely lacking. Towards this end, it will also be important
to examine these activities using in vivo tumor models.
Concluding remarks
The importance of MITF in the establishment of the mela-
nocyte lineage is clear, but its role postdevelopmentally is in-
completely understood at this time. These data suggest an
important role for MITF in survival downstream of the ca-
nonical Wnt pathway. Here we show that MITF is able to
rescue abrogation of the canonical Wnt pathway by dnTCF
in cells irrespective of their  -catenin status. However, as
MITF is retained in virtually all melanomas, including those
with deregulated  -catenin, its role might be broader than as
purely an effector for survival in the Wnt pathway. Thus,
the many signaling pathways that converge on MITF (Go-
ding, 2000; Price and Fisher, 2001) might reveal additional
cues involved in the genesis of melanomas similar to that of
the Wnt pathway.
Materials and methods
Cloning, reporter, and expression vectors
The vector pcDNA3.1- -catenin(wt) was made by excising  -catenin–
FLAG fragment from vector pCS-2- -catenin(wt)-FLAG (Liu et al., 1999)
using SpeI/NcoI, filling in with Klenow and then ligating into the EcoRV
site of pcDNA3.1( ) (Invitrogen). The pcDNA3-dnTCF1 was obtained
from Dr. H. Clevers (University Medical Center Utrecht, Utrecht, Nether-
lands) (van de Weterling et al., 1996) and pRC/CMV-cMyc from Dr. S.
Hann (Vanderbilt University School of Medicine, Nashville, TN) (Hann et
al., 1994). pRC/CMV-MITF(wt) have been described earlier (Hemesath et
al., 1994) and the pcDNA3.1-HA/MITF(dn) was made by PCR amplifica-
tion of the basic region (beginning ARALAKER) and to the last codon of
mouse MITF(del) and ligated into pcDNA3.1 with an HA-tag in frame with
the MITF coding region between the BamHI and EcoRI sites. pcDNA3.1-
hrGFP was made by excising the hrGFP coding sequence by MscI/KpnI di-
gestion from pIRES-hrGFP 2a (Stratagene) and ligated into EcoRV/KpnI of
pcDNA3.1( ) (Invitrogen). The human MITF promoter reporter (pGL2-
hMiP) consists of 484 bp of the melanocyte specific MITF promoter ( 387
to  97) as described previously (Price et al., 1998). Deletion constructs
were made by PCR and verified by sequencing. The reporter vectors TK-
TOP and TK-FOP driving luciferase were obtained commercially (Upstate
Biotechnology).
Cell cycle, MITF endogenous expression, colony-forming, and 
reporter assays
For cell cycle experiments, B16 cells and A375 (maintained in DME sup-
plemented with 10% FBS) were seeded in serum-free RPMI-1640 media
24 h before transfection in 100-mm plates. Cells were transfected using
Lipofectamine2000 (GIBCO BRL) according to the manufacturer’s recom-
mendations with the indicated vectors (4  g) and 0.3  g pcDNA3.1-
hrGFP. Cells were refed with RPMI-1640 supplemented with 10% FBS 2 h
after transfection, and on the following day they were washed and refed.
48 h after transfection, cells were harvested, fixed, and permeabilized for
flow cytometry analysis using propidium iodide to stain for DNA content.
Similarly, 501mel and SK-MEL-5 cells were also assayed using their re-
spective media preferences (see below). Endogenous MITF expression was
performed similarly as for cell cycle but the cells were harvested earlier, at
28 h posttransfection. MITF protein was stained with mouse monoclonal
C5 anti-MITF antibody, washed repeatedly, and then stained secondarily
with a R-phycoerythrin conjugated goat-anti–mouse antibody (Molecular
Probes). All samples for flow cytometry were analysed on a Becton-Dick-
inson FACS instrument using CellQuest software and each sample com-
prised of at least 10
4 gated GFP-positive events. Cell cycle and apoptosis
data were calculated using ModFit v2.0 (Becton-Dickinson). Colony-form-
ing assays were conducted in 6-well plates (2  g of total DNA/well) and
transfected with indicated vectors including 0.25  g (12.5%) of pBABE-
puro. 501mel were grown in Ham’s F10 media, SK-MEL-5 and HEK293
cells in DME, all supplemented with 10% FBS. In experiments with two ef-
fector vectors, the ratio of dnTCF to the other vector was 4:1 as indicated.
24 h after transfection cells were refed with DME/10% FBS containing 1
 g/mL puromycin for antibiotic selection. Cells were then refed with the
same media every 2 d for 10–14 d and subsequently colonies were stained
with crystal violet, photographed and measured by absorbance for relative
cell numbers. Reporter assays were made in 24-well plates (0.8  g DNA/
well) using Lipofectamine2000 (GIBCO BRL) or Fugene6 (Roche) accord-
ing to the manufacturer’s instructions. 24 h after transfection, the cells
were lysed and assayed using Dual Luciferase reagents (Promega). Lu-
ciferase values were normalized to constitutive Renilla luciferase gener-
ated by cotransfected pRL-CMV plasmid (Promega) and for the TK-FOP/
TK-TOP experiments normalized to pRL-TK (Promega).
Soft agar assays
The respective constructs were subcloned into pLHCX-retroviral back-
bones and replication incompetent virus produced in 293-EBNA cells (In-
vitrogen) by cotransfection of GagPol and VSV-G expression vectors.
High-titer viral supernatants were used to infect SK-MEL-5 in the presence
of polybrene (8  g/ml) and 48 h after infection cells were seeded at 10
5
cells per 60-mm dishes and refed every 2–3 d until macroscopic colonies
were visible. Infection was controlled by coinfection of hrGFP-expressing
retrovirus which was equal in all samples 48 h after infection.
Electrophoretic mobility shift assays and ChIPs
Electrophoretic mobility shift assays (EMSA) were performed by incubating
(total volume of 20  L) 3  g of nuclear protein, 0.2 ng of radiolabeled
probe, and 100 ng of sonicated herring sperm DNA in 10 mM Hepes, pH
7.9, 60 mM KCl, 1 mM EDTA, 1 mM DTT, and 12.5% glycerol. For
competition experiments, 5-, 15-, or 50-fold excess unlabeled MITF
oligo  (wild-type GAGTTTGACTTTGATAGCTCGTCAC or mutant GAG-
TTTGACTTTGGCAGCTCGTCAC in double-stranded configurations) was
incubated with the extract for 5 min before the addition of labeled oligo
and the incubation proceeded for an additional 20 min at room tempera-
ture. In supershift experiments, 1  L of anti– -catenin antibody (Upstate
Biotechnology) or control rabbit polyclonal antisera were added subse-
quently and incubated for an additional 20 min at room temperature. Sam-
ples were analysed on a native 30:1 (acrylamide:bis) polyacrylamide gel
run in 0.5   TBE at 4 C. ChIPs was performed in mouse B16 cells grown in
logarithmic phase in DME/10% FBS. Cells were harvested by scraping, ho-
mogenized in a low-salt buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 60
mM KCl, 5% sucrose, 0.1% NP-40, 1 mM EDTA, proteinase inhibitors) on
ice using a Dounce homogenizer. The nuclei were isolated by centrifuga-
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with 1% formaldehyde in PBS, and subsequently, the reaction quenched
by the addition of glycine to a final 125-mM concentration. Nuclei were
then spun down and resuspended in ChIPs buffer (100 mM Tris-HCl, pH
7.4, 100 mM NaCl, 60 mM KCl, 0.1% NP-40, proteinase inhibitors) and
sonicated by three 30-s pulses using a Fisher dismembranator fitted with
a microtip on ice. The samples were then precleared by an extensive
high-speed centrifugation (14,000 g, 10 min) and then precleared addi-
tionally with Ultralink protein A/G beads (Pierce Chemical Co.). Anti–
 -catenin antibody (06–734; Upstate Biotechnology), and control anti-
NFATc1 (7A6; Santa Cruz Biotechnology, Inc.) was then added to a
tenfold ChIPs buffer diluted sample and incubated on a rotator for 3 h at
room temperature. Subsequently, Ultralink protein A/G beads were
added to the samples and an additional control sample without antibody
and subsequently incubated for an additional hour. Immunoprecipitates
were washed twice with ChIPs buffer, twice with 500 mM NaCl contain-
ing ChIPs buffer and once with TE, pH 8. The immunoprecipitates were
released from the beads by incubating at 65 C for 20 min in 1%SDS/TE,
pH 6.8, and protein digested by proteinase K treatment side by side with
an additional unprecipitated sample as input control. Crosslinks were re-
leased by heating at 70 C for 10 h and DNA subsequently recovered by
extraction with phenol and chloroform at high salt (0.6 M NaAcetate, pH
8). Semiquantative PCR was then performed on samples using primers
FWD-5 -TGGCCATTAGGGAAGTCTCATGTG and REV-5 -AATTCGAA-
GAGCGACCGGCATAAAG covering the TCF/LEF binding site in the
mouse MITF promoter (EMBL/GenBank/DDBJ under accession no.
AC021060). Mouse tyrosinase promoter specific primers FWD-5 -GAG-
GCAACTATTTTAGACTGATTACTTT and REV-5 -AGGTTAATGAGTGT-
CACAGACTTC were used as a control. 
Immunofluorescence
Melanoma cells were seeded onto coverslips in 24-well plates. In transfec-
tion experiments cells were transfected 18 h postplating with pcDNA3.1-
HA/MITF(dn) using Lipofectamine2000. The day after transfection (or
plating alone), cells were fixed with 3% formaldehyde and stained with
polyclonal anti– -catenin antibody (Upstate Biotech) and secondarily with
FITC-conjugated goat-anti–rabbit antibody (Jackson ImmunoResearch Lab-
oratories) or for transfection experiments with FITC-conjugated rat high-
affinity anti-HA monoclonal antibody (Roche), all in 10% normal goat se-
rum. Subsequently, the cells were washed, counterstained with DAPI, and
photographed through a Nikon fluorescence microscope.
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